Genflow Biosciences plc

1.73pAs of Sun 8 Nov 2026, 12:00 UTC

LSE:GENFHealthcare

Ctry United Kingdom

PE (Fwd) •••

TSR 5Y CAGR (33.84%)

Div yield —

ROE —

Biotechnology

Beta (5Y) 2.27

PE TTM —

TSR TTM (13.75%)

Mkt cap £9.771M

ROIC —

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

1.95p

13.24%

(16.37%)

Hold 3|3|1|3|7

TTM

FYE 31 Dec GBP

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

1.422

Revenue£M

1.734

1.789

1.863

1.922

1.976

2.064

2.169

2.312

2.381

2.488

1.548

4.72%

4.11%

84

3.41

Revenue growth%

1.92

0.40

0.40

2.64

4.85

7.26

9.98

7.67

8.26

6.24

18.67

7.67

5.55

91

10.31

Gross margin%

19.97

19.40

16.96

17.69

17.86

18.61

18.59

19.96

17.84

17.71

2.41

18.59

18.23

31

3.04

Operating margin%

8.30

7.70

9.38

7.80

5.15

2.95

2.07

4.99

6.09

7.49

21.27

4.99

6.79

16

26.04

Net margin%

3.21

0.76

2.43

1.74

4.06

4.88

4.36

6.19

5.13

2.25

21.96

4.88

3.64

19

31.79

P/E ratio (avg)x

8.128

8.109

7.664

8.009

7.920

6.778

6.258

6.670

6.451

5.792

28.79

6.451

7.221

64

30.17

EV/EBITx

23.76

21.44

20.53

22.20

23.61

25.32

24.47

26.17

27.67

27.45

34.56

26.17

24.11

11

27.62

FCF yield (avg)%

15.22

13.07

14.42

17.01

15.63

13.20

11.57

10.52

13.28

11.43

3.11

11.57

13.24

71

3.80

FCF margin%

29.25

28.24

30.25

28.85

27.25

25.20

25.70

23.10

23.95

23.18

9.83

23.95

26.48

84

1.587

FCF / Net incomex

0.872

1.025

1.093

1.229

1.384

1.439

1.617

1.823

2.081

2.176

1.722

1.823

1.411

35

19.78

ROIC%

0.40

0.40

0.66

1.24

0.40

1.20

0.40

0.40

1.84

1.27

19.19

1.20

0.53

54

24.00

Return on equity%

22.66

23.77

21.08

22.17

22.22

21.41

22.29

20.15

22.46

22.68

29.31

22.29

22.26

52

9.40

Return on assets%

28.57

31.29

32.75

35.43

35.43

38.15

38.67

36.56

35.05

35.86

12.76

36.56

35.43

74

—

EPS£

—

—

—

—

—

—

—

—

—

—

—

(2.55%)

0.57%

—

14.22

EPS growth%

9.62

12.25

11.97

13.07

12.08

13.94

14.51

13.89

13.81

13.06

25.01

13.89

13.07

54

—

Bookvalue per sh£

—

—

—

—

—

—

—

—

—

—

—

2.89%

5.98%

—

—

FCF per share£

—

—

—

—

—

—

—

—

—

—

—

10.18%

9.50%

—

—

Dividend per sh£

—

—

—

—

—

—

—

—

—

—

—

2.48%

1.13%

—

5.85

Div yield (avg)%

29.98

32.77

34.62

32.32

35.13

34.73

31.86

34.52

33.84

34.96

28.36

34.52

34.18

73

6.41

Payout ratio%

19.00

17.03

16.16

15.69

12.78

12.50

13.20

12.01

13.81

16.08

19.55

13.20

14.75

8

556.3

Shares (diluted)M

439.2

393.2

353.8

378.1

418.3

372.8

399.5

389.4

365.9

360.1

563.5

(2.95%)

(2.52%)

70

9.11

Buyback yield%

24.50

24.36

22.90

20.72

22.64

22.60

25.07

23.72

25.49

22.79

8.61

23.72

23.31

17

0.679

D/E ratiox

1.298

1.262

1.230

1.127

1.229

1.212

1.267

1.370

1.300

1.183

1.722

1.267

1.246

18

1.594

Enterprise value£M

1.554

1.416

1.262

1.264

1.341

1.314

1.433

1.525

1.477

1.413

2.140

1.06%

(0.70%)

65

2.204

LT debt£M

1.098

1.180

1.247

1.073

1.025

1.086

1.052

1.138

1.213

1.043

0.498

0.34%

(0.91%)

36

Peers (US$13.34M)

Cap (US$)

PE

SkinBioTherapeutics plc

17.44M

—

Thalia Therapeutics Plc

13.14M

—

Aptamer Group PLC

13.13M

—

Devonian Health Group…

13.29M

—

Capital

TTM

5Y

10Y

Leveragex

1.037

0.169

0.134

EBIT/Intx

0.917

0.323

0.336

Own earn%

(42.50)

23.25

34.99

Sh yield%

14.97

57.75

57.42

Owners

Insiders/Inst%

11.33

25.71

Short interest%

5.31

SBC / revenue%

1.38

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

7

Op margin range%

2–9

$1 testx

—

Incr. ROIC%

3

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

£2.488M

4.11%

1.00×

Cost of revenue

£1.549M

4.08%

1.00×

Operating expenses

£0.495M

4.29%

1.02×